Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis - Concepedia

Concepedia

Publication | Open Access

Effect on Costs and Quality-adjusted Life-years of Treat-to-target Treatment Strategies Initiating Methotrexate, or Tocilizumab, or Their Combination in Early Rheumatoid Arthritis

DOI Full Paper Access

11

Citations

9

References

2020

Year

Maxime M. A. Verhoeven, Janneke Tekstra, Jacob M. van Laar, Attila Pethö‐Schramm, Michelle E A Borm, J. W. J. Bijlsma, Johannes W. G. Jacobs, Floris P. J. G. Lafeber, Paco M J Welsing

The Journal of Rheumatology

Abstract

Based on our analyses, early initiation of TCZ + MTX is not cost effective compared to MTX initiation in a step-up treat-to-target treatment strategy over 5 years in early RA patients.

References

	Year	Citations

Page 1